{
    "clinical_study": {
        "@rank": "85821", 
        "arm_group": {
            "arm_group_label": "tafluprost", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine how preservative free tafluprost ophthalmic solution\n      (0.0015%) is distributed in blood circulation after ocular administration in children who\n      have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general\n      will also be assessed."
        }, 
        "brief_title": "A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is a non-smoking male or female \u2264 17 years of age on the day of signing the\n             informed consent Infants must be at least 1 month of age\n\n          -  A diagnosis of primary or secondary pediatric glaucoma or ocular hypertension in one\n             or both eyes\n\n          -  A history of IOP greater than or equal to 22 mmHg in at least one eye. Newly\n             diagnosed patients may have this criterion fulfilled at the pre-study visit.\n\n          -  Patient is currently prescribed ocular hypotensive medication and who according to\n             investigator's judgement may discontinue the use at least day before the Day 1 visit,\n             or patient is treatment-na\u00efve (those who have never used used ocular hypotensive\n             medication).\n\n          -  Female patients of reproductive potential must demonstrate a negative pregnancy test\n             at the pre-study visit\n\n          -  Patient is judged to be in good health, other than having glaucoma or ocular\n             hypertension, based on medical history, physical examination, vital signs\n             measurements, and laboratory safety tests performed at the pre-study visit and/or\n             prior to administration of the initial dose of study drug\n\n          -  Patient has no clinically significant abnormality on electrocardiogram (ECG)\n             performed at the pre-study visit\n\n          -  Parent/legal guardian and/or patient have/has provided a written informed consent\n             (according to existing local regulations) and patient assent has been given as\n             applicable.\n\n          -  The patient and parent/guardian should agree to comply with study restrictions,\n             treatment plan, procedures and keep scheduled clinic visits.\n\n        Exclusion Criteria:\n\n          -  Patient currently wears continuous wear contact lenses (use of daily wear contact\n             lenses during the study is permitted)\n\n          -  One-sighted or monocular patients, including patients who cannot be dosed in both\n             eyes for any reason\n\n          -  History of goniotomy or trabeculotomy within 1 month of pre-study visit or history of\n             cataract surgery, laser surgery, filtration surgery, implant surgery or\n             cyclodestructive surgery within 3 months prior to pre-study visit in one or both\n             eyes.\n\n          -  Patient has a history or evidence of significant ocular trauma within 3 months of\n             prestudy visit\n\n          -  Patient has a history or evidence of recent ocular inflammation and/or infection\n             within 1 month of pre-study visit\n\n          -  Patient has chronic conjunctivitis, chronic keratitis or lacrimal deficiency\n\n          -  Patient is pregnant, breastfeeding, expecting to conceive within the projected\n             duration of the study\n\n          -  Patient has had major (non-ocular) surgery, loss of > 5 cc/kg of blood within 4 weeks\n             of the pre-study visit\n\n          -  Any other ocular, systemic or psychiatric disease/condition or laboratory abnormality\n\n          -  History of febrile illness within 5 days prior to start of study treatment\n\n          -  Patient has a history of hypersensitivity to any component of tafluprost eye drops,\n             or known severe or serious hypersensitivity to any prostaglandin analogue product\n             (e.g. latanoprost)\n\n          -  Patient has a history of multiple and/or severe allergies or has had an anaphylactic\n             reaction or significant intolerability to prescription or non-prescription\n             (over-the-counter) drugs or food\n\n          -  There is any concern by the investigator regarding the safe participation of a\n             patient in the study\n\n          -  Current participation in another clinical trial involving an investigational\n             drug/device, or participation in such a trial within the last 30 days from the\n             pre-study visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102750", 
            "org_study_id": "201350", 
            "secondary_id": "2013-004302-26"
        }, 
        "intervention": {
            "arm_group_label": "tafluprost", 
            "description": "0.0015% eye drops q.d, in both eyes for 7 to 9 days", 
            "intervention_name": "Preservative free tafluprost opthalmic solution", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14642"
                }, 
                "name": "University of Rochester, Flynn Eye Institute"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension", 
        "overall_contact": {
            "email": "Auli.Ropo@santen.fi", 
            "last_name": "Auli Rpop", 
            "phone": "358-40-5012416"
        }, 
        "overall_official": {
            "affiliation": "Santen Oy", 
            "last_name": "Auli Ropo", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentration of talfluprost acid.", 
            "safety_issue": "No", 
            "time_frame": "8 days +/- 1 day window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102750"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Santen Oy", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santen Oy", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}